Ascentage Pharma Presents Updated Results from Multiple Clinical Studies Demonstrating Rapid Progress in Global Clinical Development

May 27, 2022

(pdf,467KB)

Ascentage Pharma to Present Latest Clinical Data of Bcl-2 Inhibitor Lisaftoclax (APG-2575) in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas at 2022 European Hematology Association Hybrid Congress

May 23, 2022

(pdf,440KB)

(1) Poll Results of the Annual General Meeting Held on MAY 19, 2022; (2) Resignation of Non-executive Directors; (3) Change in Composition of the Remuneration Committee; and (4) Amendments to Memorandum and Articles of Association

May 19, 2022

(pdf,448KB)

The Companies Act(As Amended) Company Limited by Shares Second Amended and Restated Memorandum and Articles of Association of Ascentage Pharma Group international

May 19, 2022

(pdf,688KB)

Ascentage Pharma Announces Preclinical Data Demonstrating Olverembatinib’s Therapeutic Potential in Treating COVID-19 Published
in EMBO Molecular Medicine

May 18, 2022

(pdf,444KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April

May 6, 2022

(pdf,67KB)

Resubmission of Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March

April 28, 2022

(pdf,67KB)

Ascentage to Present Data from Seven Clinical Studies at ASCO 2022

April 28, 2022

(pdf,440KB)

Ascentage Pharma Presents Latest Results from Six Preclinical Studies at AACR Annual Meeting 2022

April 14, 2022

(pdf,64KB)

Notice of Annual General Meeting

April 13, 2022

(pdf,64KB)

Proposed Re-election of Retiring Directors, Proposed Granting of General Mandates to Issue Shares and Repurchase Shares, Proposed Amendments to the Memorandum and Articles of Association and Notice of Annual General Meeting

April 13, 2022

(pdf,64KB)

Form of Proxy for the Annual General Meeting to be Held on MAY 19, 2022

April 13, 2022

(pdf,64KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March

April 7, 2022

(pdf,64KB)

Ascentage Pharma’s MDM2-p53 Inhibitor Alrizomadlin (APG-115) Granted Rare Pediatric Disease Designation by the US FDA for the Treatment of Neuroblastoma

March 22, 2022

(pdf,428KB)

Proposed Amendments to the Amended and Restated Memorandum and Articles of Association

March 21, 2022

(pdf,428KB)

ANNOUNCEMENT OF ANNUAL RESULTS
FOR THE YEAR ENDED DECEMBER 31, 2021

March 21, 2022

(pdf,893KB)

Ascentage Pharma Announces First Patient Dosed in China in the Pivotal Phase II Study of Bcl-2 Selective Inhibitor Lisaftoclax (APG-2575) for the Treatment of R/R CLL/SLL

March 15, 2022

(pdf,428KB)

Notice of Board Meeting

March 9, 2022

(pdf,428KB)

Ascentage Pharma to Present Latest Results from Six Preclinical Studies at American Association for Cancer Research (AACR) Annual Meeting 2022

March 9, 2022

(pdf,65KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February

March 3, 2022

(pdf,65KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January

February 9, 2022

(pdf,65KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December

January 6, 2022

(pdf,65KB)

Ascentage Pharma Presents Results of Six Studies of Three Novel Drug Candidates under Development (Olverembatinib, APG-2575, and APG-1252) at the 63rd American Society of Hematology (ASH)
Annual Meeting

December 14, 2021

(pdf,466KB)

Ascentage Pharma Announces CDE’s Approval for the Phase II Pivotal Study in
China of the Bcl-2 Inhibitor Lisaftoclax (APG-2575) for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

December 13, 2021

(pdf,438KB)

Ascentage Pharma and Clover Enter into Clinical Collaboration to Jointly Develop IAP Antagonist, APG-1387, in Combination with Recombinant Human TRIAL-Trimer Fusion Protein, SCB-313,for the Treatment of Peritoneal Carcinomatosis

December 9, 2021

(pdf,74KB)

Next Day Disclosure Return

December 8, 2021

(pdf,86KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November

December 3, 2021

(pdf,66KB)

Appointment of Chief Financial Officer

November 29, 2021

(pdf,455KB)

Ascentage Pharma Announces Approval by NMPA for China’s First Approved Third-Generation
BCR-ABL TKI HQP1351 (Olverembatinib)

November 25, 2021

(pdf,455KB)

Ascentage Pharma’s core drug candidate HQP1351 (Olverembatinib) Granted Orphan Designation by the European Commission for the Treatment of Chronic Myeloid Leukemia

November 22, 2021

(pdf,449KB)

On-market Repurchase of Shares

November 11, 2021

(pdf,434KB)

Next Day Disclosure Return

November 11, 2021

(pdf,86KB)

On-market Repurchase of Shares

November 10, 2021

(pdf,434KB)

Next Day Disclosure Return

November 10, 2021

(pdf,87KB)

On-market Repurchase of Shares

November 9, 2021

(pdf,434KB)

Next Day Disclosure Return

November 9, 2021

(pdf,86KB)

Ascentage Pharma Announces Clinical Trial Agreement to Evaluate the Combination of Lisaftoclax (APG-2575) and the CDK4/6 Inhibitor IBRANCE® (Palbociclib) in the Treatment of Metastatic ER+/HER2- Breast Cancer

November 8, 2021

(pdf,475KB)

On-market Repurchase of Shares

November 8, 2021

(pdf,434KB)

Next Day Disclosure Return

November 8, 2021

(pdf,86KB)

On-market Repurchase of Shares

November 5, 2021

(pdf,475KB)

Next Day Disclosure Return

November 5, 2021

(pdf,32KB)

Abstracts on six studies of Ascentage Pharma’s three drug candidates under development (Olverembatinib, APG-2575, and APG-1252) have been
selected for oral presentation and poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting

November 5, 2021

(pdf,475KB)

Next Day Disclosure Return

November 4, 2021

(pdf,87KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October

November 4, 2021

(pdf,61KB)

On-market Repurchase of Shares

November 4, 2021

(pdf,434KB)

Resignation of Chief Financial Officer

November 1, 2021

(pdf,429KB)

Completion of the Issuance of Unlisted Warrants under Specific Mandate

October 12, 2021

(pdf,74KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September

October 7, 2021

(pdf,63KB)

Ascentage Pharma’s MDM2-p53 Inhibitor APG-115 Granted Fast Track Designation by the US FDA for the Treatment of Relapsed/Refractory Unresectable or Metastatic Melanoma

September 23, 2021

(pdf,441KB)

Poll Results of the Extraordinary General Meeting Held on September 20,2021

September 20, 2021

(pdf,438KB)

(1) Disclosable Transactions — Subscription of Commercial Paper and Structured Financial Products and (2) Supplemental Announcement in relation to the 2021 Interim Report

September 10, 2021

(pdf,114KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August

September 6, 2021

(pdf,63KB)

Form of Proxy for the Extraordinary General Meeting to be Held on September 20, 2021

August 31, 2021

(pdf,589KB)

Notice Of Extraordinary General Meeting

August 31, 2021

(pdf,82KB)

Circular (1) Connected Transaction — Proposed Grant of RSUs to Connected Selected Persons;(2) Proposed Grant of RSU Specific Mandate to Issue Shares under the 2021 RSU scheme; (3) Proposed Grant of Warrant Specific Mandate to Issue Unlisted Warrants and Warrant Shares and (4) Notice of Extraordinary General Meeting

August 31, 2021

(pdf,1MB)

Retirement of Chief Operating Officer

August 30, 2021

(pdf,61KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July(Revised)

August 29, 2021

(pdf,64KB)

Announcement of Unaudited Interim Results for the Six Months Ended JUNE 30, 2021

August 24, 2021

(pdf,437KB)

Notice of Board Meeting

August 12, 2021

(pdf,57KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July

August 5, 2021

(pdf,984KB)

Delay in Despatch of Circular in relation to (1) Proposed Issuance of Unlisted Warrants under Specific Mandate; and (2) Connected Trsansactions — Proposed Grant of Awards under the 2021 RSU Scheme to Independent Non-executive Directors and Chief Commercial Officer

July 30, 2021

(pdf,433KB)

Ascentage Pharma Announces Another Milestone Payment from Its Licensee UNITY Biotechnology, Rapidly Advancing the Clinical Development of Senolytic Drug Candidate UBX1325

July 28, 2021

(pdf,440KB)

Connected Transaction Cancellation of Proposed Grant of Awards and Proposed Re-grant of Awards under the 2021 RSU Scheme to independent non-executive Directors

July 24, 2021

(pdf,446KB)

Next Day Disclosure Return

July 23, 2021

(pdf,32KB)

Ascentage Pharma’s MDM2-p53 Inhibitor, APG-115 (Alrizomadlin), Received an Orphan Drug Designation by the FDA for the Treatment of Stage IIB-IV Melanoma

July 21, 2021

(pdf,446KB)

Ascentage Pharma Establishes Cooperation with the US National Cancer Institute to advance the Clinical Development of Ascentage Pharma’s Bcl-2/Bcl-xL inhibitor APG-1252

July 20, 2021

(pdf,441KB)

Inside Information – Entry Into of the HQP1351 Collaboration and License agreement and the APG2575 Combination Therapy Strategic Collaboration and Clinical Trial Agreement; Issuance of New Shares under General Mandate; and Proposed Issuance of Unlisted Warrants under Specific Mandate

July 14, 2021

(pdf,159KB)

Connected Transaction Proposed Grant of Awards under the 2021 RSU Scheme to Independent Non-executive Directors Appointment of Independent Financial Adviser

July 14, 2021

(pdf,446KB)

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June

July 6, 2021

(pdf,278KB)

Next Day Disclosure Return

June 29, 2021

(pdf,169KB)

2020 Environmental, Social and Governance Report

June 29, 2021

(pdf,5MB)

CLARIFICATION ANNOUNCEMENT GRANT OF AWARDS UNDER THE 2021 RSU SCHEME TO THE INDEPENDENT SELECTED PERSONS

June 25, 2021

(pdf,433KB)

UPDATE ANNOUNCEMENT GRANT OF AWARDS UNDE